-
1
-
-
84862193216
-
Management of cardiovascular risk: the importance of meeting lipid targets.
-
Gotto AM Jr, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. Am J Cardiol 2012;110(1 Suppl):3A-14A.
-
(2012)
Am J Cardiol
, vol.110
, Issue.1 SUPPL.
-
-
Gotto Jr., A.M.1
Moon, J.E.2
-
2
-
-
84883337835
-
Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks.
-
Minder CM, Blumenthal RS, Blaha MJ. Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks. Curr Opin Cardiol 2013;28:554-60.
-
(2013)
Curr Opin Cardiol
, vol.28
, pp. 554-560
-
-
Minder, C.M.1
Blumenthal, R.S.2
Blaha, M.J.3
-
3
-
-
0027364367
-
Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins.
-
Metz SA, Rabaglia ME, Stock JB, Kowluru A. Modulation of insulin secretion from normal rat islets by inhibitors of the post-translational modifications of GTP-binding proteins. Biochem J 1993;295(Pt 1):31-40.
-
(1993)
Biochem J
, vol.295
, Issue.PART 1
, pp. 31-40
-
-
Metz, S.A.1
Rabaglia, M.E.2
Stock, J.B.3
Kowluru, A.4
-
4
-
-
0028938714
-
A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia.
-
Ohrvall M, Lithell H, Johansson J, Vessby B. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism 1995;44:212-7.
-
(1995)
Metabolism
, vol.44
, pp. 212-217
-
-
Ohrvall, M.1
Lithell, H.2
Johansson, J.3
Vessby, B.4
-
5
-
-
78751680407
-
Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.
-
Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, Eyawo O, Guyatt G, Berwanger O, Briel M. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011;104:109-24.
-
(2011)
QJM
, vol.104
, pp. 109-124
-
-
Mills, E.J.1
Wu, P.2
Chong, G.3
Ghement, I.4
Singh, S.5
Akl, E.A.6
Eyawo, O.7
Guyatt, G.8
Berwanger, O.9
Briel, M.10
-
6
-
-
70349664292
-
Statin therapy and risk of developing type 2 diabetes: a meta-analysis.
-
Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924-9.
-
(2009)
Diabetes Care
, vol.32
, pp. 1924-1929
-
-
Rajpathak, S.N.1
Kumbhani, D.J.2
Crandall, J.3
Barzilai, N.4
Alderman, M.5
Ridker, P.M.6
-
7
-
-
77549087054
-
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
-
Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
-
(2010)
Lancet
, vol.375
, pp. 735-742
-
-
Sattar, N.1
Preiss, D.2
Murray, H.M.3
Welsh, P.4
Buckley, B.M.5
de Craen, A.J.6
Seshasai, S.R.7
McMurray, J.J.8
Freeman, D.J.9
Jukema, J.W.10
Macfarlane, P.W.11
Packard, C.J.12
Stott, D.J.13
Westendorp, R.G.14
Shepherd, J.15
Davis, B.R.16
Pressel, S.L.17
Marchioli, R.18
Marfisi, R.M.19
Maggioni, A.P.20
Tavazzi, L.21
Tognoni, G.22
Kjekshus, J.23
Pedersen, T.R.24
Cook, T.J.25
Gotto, A.M.26
Clearfield, M.B.27
Downs, J.R.28
Nakamura, H.29
Ohashi, Y.30
Mizuno, K.31
Ray, K.K.32
Ford, I.33
more..
-
8
-
-
79959428660
-
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
-
Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-64.
-
(2011)
JAMA
, vol.305
, pp. 2556-2564
-
-
Preiss, D.1
Seshasai, S.R.2
Welsh, P.3
Murphy, S.A.4
Ho, J.E.5
Waters, D.D.6
DeMicco, D.A.7
Barter, P.8
Cannon, C.P.9
Sabatine, M.S.10
Braunwald, E.11
Kastelein, J.J.12
de Lemos, J.A.13
Blazing, M.A.14
Pedersen, T.R.15
Tikkanen, M.J.16
Sattar, N.17
Ray, K.K.18
-
9
-
-
0035936527
-
Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.
-
Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.
-
(2001)
Circulation
, vol.103
, pp. 357-362
-
-
Freeman, D.J.1
Norrie, J.2
Sattar, N.3
Neely, R.D.4
Cobbe, S.M.5
Ford, I.6
Isles, C.7
Lorimer, A.R.8
Macfarlane, P.W.9
McKillop, J.H.10
Packard, C.J.11
Shepherd, J.12
Gaw, A.13
-
10
-
-
56749106312
-
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
-
JUPITER Study Group.
-
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-207.
-
(2008)
N Engl J Med
, vol.359
, pp. 2195-2207
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.3
Genest, J.4
Gotto Jr., A.M.5
Kastelein, J.J.6
Koenig, W.7
Libby, P.8
Lorenzatti, A.J.9
MacFadyen, J.G.10
Nordestgaard, B.G.11
Shepherd, J.12
Willerson, J.T.13
Glynn, R.J.14
-
11
-
-
84892155439
-
-
U.S. Food and Drug Administration: FDA drug safety communication: important safety label changes to cholesterol lowering statin drugs. Available from: (update 2012 Feb 28).
-
U.S. Food and Drug Administration: FDA drug safety communication: important safety label changes to cholesterol lowering statin drugs. Available from: http://www.fda.gov/drugs/drugsafety/ucm293101.htm (update 2012 Feb 28).
-
-
-
-
12
-
-
0037840242
-
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
-
Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
-
(2003)
Lancet
, vol.361
, pp. 2005-2016
-
-
Collins, R.1
Armitage, J.2
Parish, S.3
Sleigh, P.4
Peto, R.5
-
13
-
-
10644259543
-
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
-
Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 2004;64 Suppl 2:43-60.
-
(2004)
Drugs
, vol.64
, Issue.SUPPL. 2
, pp. 43-60
-
-
Sever, P.S.1
Dahlof, B.2
Poulter, N.R.3
Wedel, H.4
Beevers, G.5
Caulfield, M.6
Collins, R.7
Kjeldsen, S.E.8
Kristinsson, A.9
McInnes, G.T.10
Mehlsen, J.11
Nieminen, M.12
O'Brien, E.13
Ostergren, J.14
-
14
-
-
10744228379
-
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.
-
Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A; LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003;26:2713-21.
-
(2003)
Diabetes Care
, vol.26
, pp. 2713-2721
-
-
Keech, A.1
Colquhoun, D.2
Best, J.3
Kirby, A.4
Simes, R.J.5
Hunt, D.6
Hague, W.7
Beller, E.8
Arulchelvam, M.9
Baker, J.10
Tonkin, A.11
-
15
-
-
36549030340
-
Rosuvastatin in older patients with systolic heart failure.
-
CORONA Group.
-
Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamenskỳ G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-61.
-
(2007)
N Engl J Med
, vol.357
, pp. 2248-2261
-
-
Kjekshus, J.1
Apetrei, E.2
Barrios, V.3
Bohm, M.4
Cleland, J.G.5
Cornel, J.H.6
Dunselman, P.7
Fonseca, C.8
Goudev, A.9
Grande, P.10
Gullestad, L.11
Hjalmarson, A.12
Hradec, J.13
Janosi, A.14
Kamenskỳ, G.15
Komajda, M.16
Korewicki, J.17
Kuusi, T.18
Mach, F.19
Mareev, V.20
McMurray, J.J.21
Ranjith, N.22
Schaufelberger, M.23
Vanhaecke, J.24
van Veldhuisen, D.J.25
Waagstein, F.26
Wedel, H.27
Wikstrand, J.28
more..
-
16
-
-
84864861863
-
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.
-
Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565-71.
-
(2012)
Lancet
, vol.380
, pp. 565-571
-
-
Ridker, P.M.1
Pradhan, A.2
MacFadyen, J.G.3
Libby, P.4
Glynn, R.J.5
-
17
-
-
84859109538
-
Pharmacotherapy: statins and new-onset diabetes: the important questions.
-
Preiss D, Sattar N. Pharmacotherapy: statins and new-onset diabetes: the important questions. Nat Rev Cardiol 2012;9:190-2.
-
(2012)
Nat Rev Cardiol
, vol.9
, pp. 190-192
-
-
Preiss, D.1
Sattar, N.2
-
18
-
-
79953183649
-
Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials.
-
Waters DD, Ho JE, DeMicco DA, Breazna A, Arsenault BJ, Wun CC, Kastelein JJ, Colhoun H, Barter P. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011;57:1535-45.
-
(2011)
J Am Coll Cardiol
, vol.57
, pp. 1535-1545
-
-
Waters, D.D.1
Ho, J.E.2
DeMicco, D.A.3
Breazna, A.4
Arsenault, B.J.5
Wun, C.C.6
Kastelein, J.J.7
Colhoun, H.8
Barter, P.9
-
19
-
-
33846464226
-
Safety and efficacy of statins in Asians.
-
Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007;99:410-4.
-
(2007)
Am J Cardiol
, vol.99
, pp. 410-414
-
-
Liao, J.K.1
-
20
-
-
84862908066
-
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative.
-
Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, Rahilly-Tierny C, Thomas F, Berger JS, Ockene JK, Curb JD, Ma Y. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172:144-52.
-
(2012)
Arch Intern Med
, vol.172
, pp. 144-152
-
-
Culver, A.L.1
Ockene, I.S.2
Balasubramanian, R.3
Olendzki, B.C.4
Sepavich, D.M.5
Wactawski-Wende, J.6
Manson, J.E.7
Qiao, Y.8
Liu, S.9
Merriam, P.A.10
Rahilly-Tierny, C.11
Thomas, F.12
Berger, J.S.13
Ockene, J.K.14
Curb, J.D.15
Ma, Y.16
-
21
-
-
13844317762
-
Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome.
-
Guclu F, Ozmen B, Hekimsoy Z, Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 2004;58:614-8.
-
(2004)
Biomed Pharmacother
, vol.58
, pp. 614-618
-
-
Guclu, F.1
Ozmen, B.2
Hekimsoy, Z.3
Kirmaz, C.4
-
22
-
-
79952106340
-
Differential metabolic effects of distinct statins.
-
Koh KK, Sakuma I, Quon MJ. Differential metabolic effects of distinct statins. Atherosclerosis 2011;215:1-8.
-
(2011)
Atherosclerosis
, vol.215
, pp. 1-8
-
-
Koh, K.K.1
Sakuma, I.2
Quon, M.J.3
-
23
-
-
34548500220
-
Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease.
-
Sugiyama S, Fukushima H, Kugiyama K, Maruyoshi H, Kojima S, Funahashi T, Sakamoto T, Horibata Y, Watanabe K, Koga H, Sugamura K, Otsuka F, Shimomura I, Ogawa H. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007;194:e43-51.
-
(2007)
Atherosclerosis
, vol.194
-
-
Sugiyama, S.1
Fukushima, H.2
Kugiyama, K.3
Maruyoshi, H.4
Kojima, S.5
Funahashi, T.6
Sakamoto, T.7
Horibata, Y.8
Watanabe, K.9
Koga, H.10
Sugamura, K.11
Otsuka, F.12
Shimomura, I.13
Ogawa, H.14
-
24
-
-
38049004875
-
Effect of pravastatin on the development of diabetes and adiponectin production.
-
Takagi T, Matsuda M, Abe M, Kobayashi H, Fukuhara A, Komuro R, Kihara S, Caslake MJ, McMahon A, Shepherd J, Funahashi T, Shimomura I. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008;196:114-21.
-
(2008)
Atherosclerosis
, vol.196
, pp. 114-121
-
-
Takagi, T.1
Matsuda, M.2
Abe, M.3
Kobayashi, H.4
Fukuhara, A.5
Komuro, R.6
Kihara, S.7
Caslake, M.J.8
McMahon, A.9
Shepherd, J.10
Funahashi, T.11
Shimomura, I.12
-
25
-
-
73749087527
-
Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis.
-
Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010;87:98-107.
-
(2010)
Diabetes Res Clin Pract
, vol.87
, pp. 98-107
-
-
Baker, W.L.1
Talati, R.2
White, C.M.3
Coleman, C.I.4
-
26
-
-
84878773567
-
Risk of incident diabetes among patients treated with statins: population based study.
-
Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013;346:f2610.
-
(2013)
BMJ
, vol.346
-
-
Carter, A.A.1
Gomes, T.2
Camacho, X.3
Juurlink, D.N.4
Shah, B.R.5
Mamdani, M.M.6
-
27
-
-
38049033935
-
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
-
Cholesterol Treatment Trialists' (C.T.T) Collaborators
-
Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25.
-
(2008)
Lancet
, vol.371
, pp. 117-125
-
-
Kearney, P.M.1
Blackwell, L.2
Collins, R.3
Keech, A.4
Simes, J.5
Peto, R.6
Armitage, J.7
Baigent, C.8
-
28
-
-
78651338445
-
Standards of medical care in diabetes: 2011.
-
American Diabetes Association
-
American Diabetes Association. Standards of medical care in diabetes: 2011. Diabetes Care 2011;34(Suppl 1):S11-61.
-
(2011)
Diabetes Care
, vol.34
, Issue.SUPPL. 1
-
-
-
31
-
-
84865562586
-
Statins are diabetogenic: myth or reality?
-
Sattar N, Taskinen MR. Statins are diabetogenic: myth or reality? Atheroscler Suppl 2012;13:1-10.
-
(2012)
Atheroscler Suppl
, vol.13
, pp. 1-10
-
-
Sattar, N.1
Taskinen, M.R.2
-
32
-
-
0032978644
-
Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.
-
Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999;126:1205-13.
-
(1999)
Br J Pharmacol
, vol.126
, pp. 1205-1213
-
-
Yada, T.1
Nakata, M.2
Shiraishi, T.3
Kakei, M.4
-
33
-
-
53249121824
-
Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells.
-
Xia F, Xie L, Mihic A, Gao X, Chen Y, Gaisano HY, Tsushima RG. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. Endocrinology 2008;149:5136-45.
-
(2008)
Endocrinology
, vol.149
, pp. 5136-5145
-
-
Xia, F.1
Xie, L.2
Mihic, A.3
Gao, X.4
Chen, Y.5
Gaisano, H.Y.6
Tsushima, R.G.7
-
34
-
-
34548386258
-
Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction.
-
Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW. Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction. Diabetes 2007;56:2328-38.
-
(2007)
Diabetes
, vol.56
, pp. 2328-2338
-
-
Hao, M.1
Head, W.S.2
Gunawardana, S.C.3
Hasty, A.H.4
Piston, D.W.5
-
35
-
-
24344509230
-
Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients.
-
Mabuchi H, Higashikata T, Kawashiri M, Katsuda S, Mizuno M, Nohara A, Inazu A, Koizumi J, Kobayashi J. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 2005;12:111-9.
-
(2005)
J Atheroscler Thromb
, vol.12
, pp. 111-119
-
-
Mabuchi, H.1
Higashikata, T.2
Kawashiri, M.3
Katsuda, S.4
Mizuno, M.5
Nohara, A.6
Inazu, A.7
Koizumi, J.8
Kobayashi, J.9
-
36
-
-
84866890172
-
Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes.
-
Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev 2012;40:188-94.
-
(2012)
Exerc Sport Sci Rev
, vol.40
, pp. 188-194
-
-
Parker, B.A.1
Thompson, P.D.2
-
37
-
-
77954503073
-
Coenzyme q10 and statin-induced mitochondrial dysfunction.
-
Deichmann R, Lavie C, Andrews S. Coenzyme q10 and statin-induced mitochondrial dysfunction. Ochsner J 2010;10:16-21.
-
(2010)
Ochsner J
, vol.10
, pp. 16-21
-
-
Deichmann, R.1
Lavie, C.2
Andrews, S.3
-
38
-
-
33745794259
-
Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control.
-
Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006;49:1881-92.
-
(2006)
Diabetologia
, vol.49
, pp. 1881-1892
-
-
Nakata, M.1
Nagasaka, S.2
Kusaka, I.3
Matsuoka, H.4
Ishibashi, S.5
Yada, T.6
-
39
-
-
0035798232
-
Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes.
-
Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001;507:357-61.
-
(2001)
FEBS Lett
, vol.507
, pp. 357-361
-
-
Chamberlain, L.H.1
-
40
-
-
0033510053
-
Nitric oxide induces apoptosis via Ca2+-dependent processes in the pancreatic beta-cell line MIN6.
-
Nakata M, Uto N, Maruyama I, Yada T. Nitric oxide induces apoptosis via Ca2+-dependent processes in the pancreatic beta-cell line MIN6. Cell Struct Funct 1999;24:451-5.
-
(1999)
Cell Struct Funct
, vol.24
, pp. 451-455
-
-
Nakata, M.1
Uto, N.2
Maruyama, I.3
Yada, T.4
-
41
-
-
33747882182
-
Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia.
-
Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, Babiychuk EB. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 2006;210:94-102.
-
(2006)
J Pathol
, vol.210
, pp. 94-102
-
-
Draeger, A.1
Monastyrskaya, K.2
Mohaupt, M.3
Hoppeler, H.4
Savolainen, H.5
Allemann, C.6
Babiychuk, E.B.7
|